Editas Medicine, Inc. EDIT · Stock Open Editas Medicine, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Editas Medicine, Inc. Analysis (EDIT)
Is Editas Medicine, Inc. a good investment? Editas Medicine, Inc. (EDIT) is currently trading at 2.75 USD. Market analysts have a consensus price target of 5.90 USD. This suggests a potential upside from current levels.
Earnings Schedule: Editas Medicine, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -0.75.
Investor FAQ
Does Editas Medicine, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Editas Medicine, Inc.?
Editas Medicine, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -0.68.
Company Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Community Discussion